ViroPharma's Camvia gets EU orphan status

Pennsylvania, USA-based ViroPharma says that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) has granted orphan drug designation for Camvia (maribavir), for the prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity.

Under EMEA guidelines, Orphan Medicinal Product Designation provides 10 years of potential market exclusivity if the product candidate is approved for marketing in the European Union.

Thierry Darcis, ViroPharma's vice president and general manager, Europe, commented: "this designation clearly recognizes the potential to address great unmet medical needs with Camvia as we work to maximize the global value of the drug. This designation from the EMEA adds additional momentum as we continue to develop Camvia for transplant-related cytomegalovirus disease."